All Stories

  1. The role of kynurenines in migraine-related neuroimmune pathways

    Article • The Journal of Headache and Pain, August 2024, Springer Science + Business Media

    Professor László Vécsei

  2. Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine

    Article • Mini-Reviews in Medicinal Chemistry, April 2020, Bentham Science Publishers

    Professor László Vécsei

  3. The Therapeutic Impact of New Migraine Discoveries

    Article • Current Medicinal Chemistry, December 2019, Bentham Science Publishers

    Professor László Vécsei, Janos TAJTI, Lars Edvinsson

  4. Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias

    Article • CNS & Neurological Disorders - Drug Targets, July 2019, Bentham Science Publishers

    Professor László Vécsei, Laszlo Szpisjak

  5. Therapeutic strategies that act on the peripheral nervous system in primary headache disorders

    Article • Expert Review of Neurotherapeutics, May 2019, Taylor & Francis

    Janos TAJTI, Aliz Nyari, Professor László Vécsei

  6. Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects

    Article • Current Medicinal Chemistry, February 2019, Bentham Science Publishers

    Professor László Vécsei

  7. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease

    Article • Expert Opinion on Therapeutic Targets, November 2018, Taylor & Francis

    Professor László Vécsei

  8. Treating status migrainosus in the emergency setting: what is the best strategy?

    Article • Expert Opinion on Pharmacotherapy, September 2018, Taylor & Francis

    Professor László Vécsei, Janos TAJTI, Aliz Nyari

  9. Chronic 17β-estradiol pretreatment has pronociceptive effect on behavioral and morphological changes induced by orofacial formalin in ovariectomized rats

    Article • Journal of Pain Research, September 2018, Dove Medical Press

    Professor László Vécsei, Dr Arpad Pardutz

  10. Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod

    Article • Current Drug Targets, April 2018, Bentham Science Publishers

    Professor László Vécsei

  11. Alzheimer’s Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines

    Article • Journal of Alzheimer’s Disease, February 2018, IOS Press

    Professor László Vécsei

  12. The rs13388259 Intergenic Polymorphism in the Genomic Context of theBCYRN1Gene Is Associated with Parkinson’s Disease in the Hungarian Population

    Article • Parkinson s Disease, January 2018, Hindawi Publishing Corporation

    Nikoletta Nagy, Professor László Vécsei

  13. Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects

    Article • Current Medicinal Chemistry, October 2017, Bentham Science Publishers

    Professor László Vécsei, Janos TAJTI, Lars Edvinsson

  14. Monoamine Oxidase B Inhibitors in Parkinson's Disease

    Article • CNS & Neurological Disorders - Drug Targets, July 2017, Bentham Science Publishers

    Professor László Vécsei

  15. Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects

    Article • Current Medicinal Chemistry, June 2017, Bentham Science Publishers

    Professor László Vécsei

  16. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin

    Article • CNS & Neurological Disorders - Drug Targets, April 2017, Bentham Science Publishers

    Professor László Vécsei

  17. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy

    Article • Drug Design Development and Therapy, January 2017, Dove Medical Press

    Professor László Vécsei

  18. Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues

    Article • Drug Design Development and Therapy, December 2016, Dove Medical Press

    Professor László Vécsei

  19. The modulatory effect of anandamide on nitroglycerin-induced sensitization in the trigeminal system of the rat

    Article • Cephalalgia, July 2016, SAGE Publications

    Professor László Vécsei

  20. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer’s Disease: Shortcomings in Prodromal Diagnosis

    Article • Journal of Alzheimer’s Disease, July 2016, IOS Press

    Professor László Vécsei

  21. Shapiro-szindróma, azaz a termoregulációs zavar ritka esete

    Article • Orvosi Hetilap, February 2016, Akademiai Kiado

    Professor László Vécsei

  22. A kinureninrendszer és a stressz

    Article • Orvosi Hetilap, August 2015, Akademiai Kiado

    Professor László Vécsei

  23. Alzheimer’s Disease, Astrocytes and Kynurenines

    Article • Current Alzheimer Research, May 2015, Bentham Science Publishers

    Professor László Vécsei

  24. Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability

    Article • CNS & Neurological Disorders - Drug Targets, May 2015, Bentham Science Publishers

    Professor László Vécsei

  25. Role of Pituitary Adenylate Cyclase-Activating Polypeptide in Nociception and Migraine

    Article • CNS & Neurological Disorders - Drug Targets, May 2015, Bentham Science Publishers

    Professor László Vécsei

  26. Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design

    Article • Current Pharmaceutical Design, April 2015, Bentham Science Publishers

    Professor László Vécsei

  27. Effect of Probenecid on the Pain-Related Behaviour and Morphological Markers in Orofacial Formalin Test of the Rat

    Article • CNS & Neurological Disorders - Drug Targets, April 2015, Bentham Science Publishers

    Professor László Vécsei

  28. Drug safety and tolerability in prophylactic migraine treatment

    Article • Expert Opinion on Drug Safety, February 2015, Informa Healthcare

    Professor László Vécsei

  29. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

    Article • Expert Opinion on Drug Metabolism & Toxicology, September 2014, Informa Healthcare

    Professor László Vécsei

  30. CGRP antagonists and antibodies for the treatment of migraine

    Article • Expert Opinion on Investigational Drugs, September 2014, Informa Healthcare

    Professor László Vécsei

  31. Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood–brain barrier permeability

    Article • Drug Design Development and Therapy, September 2013, Taylor & Francis

    Professor László Vécsei, Dr Arpad Pardutz, Janos TAJTI